

Guanylin and *E. coli* Heat-Stable Enterotoxin Induce Chloride Secretion through Direct Interaction with Basolateral Compartment of Rat and Human Colonic Cells

FABIO ALBANO, GIULIO DE MARCO, ROBERTO BERNI CANANI, PIA CIRILLO, VITTORIA BUCCIGROSSI, RALPH A. GIANNELLA, AND ALFREDO GUARINO

Department of Pediatrics [F.A., G.D.M., R.B.C., P.C., V.B., A.G.], University "Federico II," 80131 Naples, Italy, Division of Digestive Diseases [R.A.G.], University of Cincinnati College of Medicine, Veterans Administration Medical Center, Cincinnati, Ohio 45267

ABSTRACT

We previously detected specific binding activity of *Escherichia coli* heat-stable enterotoxin (ST), the guanylin exogenous ligand, in rat colonic basolateral membranes. Because guanylin circulates in the bloodstream, we tested the hypothesis that it modulates intestinal ion transport by acting on the serosal side of intestinal cells. The effects of the mucosal and serosal addition of ST and guanylin on ion transport were investigated in the rat proximal colon and in Caco-2 cells in Ussing chambers, by monitoring short-circuit current (Isc). cGMP concentration was measured in Caco-2 cells by RIA. Mucosal ST addition induced an increase in Isc in rat proximal colon consistent with anion secretion. Serosal addition induced the same effects but to a lesser extent. The electrical effects observed in Caco-2 cells paralleled those observed in rat proximal colon. A pattern similar to the electrical response was observed with cGMP concentration. Guanylin addition to either side of Caco-2 cells induced the same effects as ST, although to a lesser extent. In all conditions,

the electrical effect disappeared in the absence of chloride. ST directly interacts with basolateral receptors in the large intestine inducing chloride secretion through an increase of cGMP. However, the serosal effects are less pronounced compared with those observed with mucosal addition. Guanylin shows the same pattern, suggesting that it plays a role in the regulation of ion transport in the colon, but the relative importance of serosally mediated secretion remains to be determined. (*Pediatr Res* 58: 159–163, 2005)

Abbreviations

BBM, brush border membrane
BLM, basolateral membranes
CFTR, cystic fibrosis transmembrane regulator
GC-C, guanylyl cyclase C
Isc, short-circuit current
ST, heat-stable enterotoxin

ST elaborated by *Escherichia coli* and other bacteria are structurally related peptides that activate the transmembrane protein GC-C, located on the intestinal BBM of small and large intestinal enterocytes (1–3). ST binding to GC-C results in the generation of cGMP (4,5), which activates type-II cGMP-dependent protein kinase, leading to the phosphorylation of the CFTR and eventually results in chloride and bicarbonate secretion (6–8). The clinical manifestation of ST effects is diarrhea. This is of the secretory type and is particularly severe in younger infants (9).

Because the endogenous ligands of GC-C receptor, guanylin, and uroguanylin (10,11) activate the same pathway and cause an increase in Isc in intestinal epithelial cells, it has been suggested that they play a role in regulating intestinal fluid secretion. In most mammalian species, both peptides are produced predominantly in the intestine, although uroguanylin is also expressed in the kidney (12–14). Proguanylin and prouroguanylin are secreted into the intestinal lumen but they are also detected in the bloodstream as 11-kD prohormones and are each cleaved to the active 15 amino acid carboxy termini that bind GC-C (15–17). Circulating uroguanylin induces natriuresis, kaliuresis, and diuresis in isolated perfused rat kidney. It has been suggested that uroguanylin represents a gut-to-kidney signaling hormone that, upon ingestion of high-salt meals, causes natriuresis in anticipation of increased intestinal salt absorption (18,19). However, guanylin and uroguanylin may have other physiologic roles (20,21), including the acti-

Received May 20, 2004; accepted November 24, 2004.

Correspondence: Alfredo Guarino, M.D., Department of Pediatrics, University "Federico II," Via S. Pansini 5, 80131 Naples, Italy; e-mail: alfguari@unina.it

Supported by a grant (number 50D28) from the Istituto Superiore di Sanità, 4th AIDS Research Project.

DOI: 10.1203/01.PDR.0000163380.96434.B9

vation of a cGMP signal transduction pathway that may take part in the regulation of the turnover of epithelial cells by continuous replenishment of the epithelial cells (22,23).

ST is more potent than either guanylin or uroguanylin in stimulating intestinal secretion as judged by the effects on Isc of intestinal epithelium mounted in Ussing chambers. Because of these properties, ST is commonly used to study the GC-C-dependent secretory system in the rat and human intestine (24–28). Receptors for ST are located in the BBM. The addition of ST to the mucosal side of human colonic T84 cell stimulated active chloride secretion and the production of cGMP (26). Furthermore, ST showed similar binding kinetics in human intestinal and in colon-derived Caco-2 cells. Receptors for ST have been detected in the rat colon (28).

We have previously shown that ST binds specifically to highly purified BLM from rat colon (29). Because the endogenous ligands for GC-C, guanylin, and uroguanylin circulate in the blood, we hypothesized that guanylin or ST might be active when applied to the serosal surface of the colon.

To test this, we performed experiments with addition of ST to either side of rat colon mounted in Ussing chambers. We also used cell monolayers from human colon carcinoma cell line Caco-2. The experiments were repeated using guanylin to test our original hypothesis.

MATERIALS AND METHODS

Animals. Sprague-Dawley rats weighing 200–250 g were used. Animals were fed Purina rat chow and fasted 6 h before experiments but were allowed free access to water.

Cell growth and culture. The human intestinal epithelial cell line Caco-2 has been established from a moderately well-differentiated colon carcinoma. Caco-2 cells were grown in Dulbecco's modified Eagle minimum essential medium with high glucose concentration (4.5 g/L) at 37°C in 5% CO₂ atmosphere as previously described (30). The medium was supplemented with 10% FCS, 1% nonessential amino acids, penicillin (50 million units/mL), and streptomycin (50 µg/mL). The medium was changed daily.

Cells were grown on uncoated, nontransparent polycarbonate Transwell filters (0.4 µm pore size, 24.5 mm diameter; 2×10^6 cells were plated per filter). Cells were between the 50th and 70th passages and were used for intestinal transport studies 15 d after seeding when they formed a single layer of confluent cells connected by tight junctions and produce transepithelial electrical resistance (TEER) typical of polarized epithelial cells.

Intestinal ion transport studies in animals. Rats were killed by cervical dislocation and a 5-cm segment of proximal colon, 1–2 cm distal to the cecal-colonic junction, was rapidly removed and rinsed with ice-cold Ringer solution with the following composition: 53 mM NaCl, 5 mM KCl, 30.5 mM Na₂SO₄, 25 mM mannitol, 1.69 mM Na₂HPO₄, 0.3 mM NaH₂PO₄, 1.25 mM CaCl₂, 1.1 mM MgCl₂, and 25 mM NaHCO₃. Four paired fragments of unstripped colonic mucosa were mounted in Ussing chambers. In each experiment, one fragment served as control of baseline electrical parameters.

The solution was maintained at 37°C with water-jacketed reservoirs connected to a thermostated circulating pump and constantly gassed with 95% O₂/5% CO₂. Transepithelial potential difference (PD), Isc, and tissue ionic conductance (G) were measured as previously described (30). Isc is expressed as µA/cm², G as mS/cm², and PD as mV. Electrical parameters were recorded before and at various times after the addition of ST to the mucosal or the serosal side.

All animal experimentation described was approved by the Institutional Animal Care and Use Committee.

Intestinal ion transport studies in Caco-2 cells. Each filter was mounted as a flat sheet between the mucosal and serosal compartment of Ussing chambers. Each compartment contained 10 mL of Ringer's solution with the following composition: 114 mM NaCl, 5 mM KCl, 1.65 mM Na₂HPO₄, 0.3 mM NaH₂PO₄, 1.25 mM CaCl₂, 1.1 mM MgCl₂, 25.0 mM NaHCO₃, and 10.0 mM glucose.

ST or guanylin were added to either the mucosal or serosal side of the filter.

To see whether the electrical effect was consistent with anion secretion rather than cation absorption, experiments were performed, both in cells and

rats, in Cl⁻-free Ringer's solution in which SO₄⁻ replaced Cl⁻ ions at equimolar concentration.

Cell and rat colonic fragment viability was assessed at the end of each experiment in paired controls by measuring the electrical response to serosal addition of 5 mmol of theophylline. An Isc increase of at least 3-fold compared with the preaddition value was considered proof of cell viability.

Determination of cGMP concentrations. After completing the Ussing chamber studies, the filter was rapidly removed from each chamber, transferred to ice-cold 5% trichloroacetic acid (TCA) and homogenized. The homogenate was centrifuged at 2000 g for 3 min at 4°C, and the supernatant was collected and evaporated to dryness under vacuum (Speed VAC 110, Savant Instruments, Farmingdale, NY). The dried sample was redissolved in 0.5 M acetate buffer, pH 5.8 with 0.01% sodium azide, and cGMP concentration was measured using a RIA commercial kit (cGMP ¹²⁵I assay system; Amersham Pharmacia Biotech UK, Ltd., Little Chalfont, Buckinghamshire, UK), according to the manufacturer's instructions. Results were calculated as picomoles of cGMP per square centimeter and expressed as fold increase over basal level.

ELISA assay for ST. The presence of ST in the fluid bathing the mucosal surface of epithelium after ST serosal addition was tested by an ELISA test with MAb raised against pure 18-amino acid *E. coli* ST as described elsewhere (31).

Chemicals. All chemicals, including ST and guanylin, were of reagent grade and were obtained from Sigma-Aldrich Italy (Milan, Italy); culture media were from Invitrogen (Milan, Italy). Transwell filters were from Costar (Costar Italia, Milan, Italy).

Statistics. Each experiment was run in duplicate and repeated at least four times. Results are expressed as means ± SD. Two-tailed, unpaired *t* test was applied to evaluate statistical significance. A value of *p* < 0.05 was considered statistically significant.

RESULTS

Electrical effects of ST in rat colon. The addition of ST (10⁻⁶ M) to the mucosal side of rat colon induced a prompt increase of Isc that reached a maximum 2 min after addition and then slowly decreased toward baseline (Fig. 1). Isc increase was entirely related to a modification of PD inasmuch as no variations of G were observed.

The addition of ST to the serosal side also induced a rise of Isc that was very similar to that observed with mucosal addition but with a reduced Isc peak (Fig. 1). Both the mucosal and




Figure 1. Time course of the effect of the addition of ST to the mucosal (◆) or serosal (■) compartments on Isc of rat colon mounted in an Ussing chamber. The addition of ST (10⁻⁶M) to each side of colonic specimens induced a rapid increase in Isc. The simultaneous addition of ST to the mucosal and serosal (△) compartments of rat proximal colon in a concentration capable of inducing a maximal response induced no further increase in Isc. No increase in Isc was observed, in the absence of Cl⁻, upon either the mucosal (×) or serosal (data not shown) addition of ST. Mean and SD of the peak effect of ST in at least four experiments is shown in the inset (**p* < 0.05 vs controls).

serosal effects were dose dependent, and on both sides the maximal effect was observed with ST concentration of 10^{-6} M (data not shown). After determining the dose-response, ST was simultaneously added to both the mucosal and serosal compartments in the concentration capable of eliciting the maximal effect, and it did not correspond to the sum of those observed with ST addition to either side. A further Isc increase compared with the mucosal effect was consistently observed (Fig. 1). However, this increase did not reach the level of statistical significance.

All electrical modifications were inhibited in chloride-free buffer (Fig. 1).

Electrical effects of ST in Caco-2 cells. The addition of ST (10^{-6} M) to the mucosal side of Caco-2 cells induced an electrical response that was similar to that observed in rat proximal colon (Fig. 2). Half maximal effect was observed at a concentration of 5×10^{-7} (Fig. 3A). The Isc response was maximal at a ST concentration of 10^{-6} M. Higher concentrations of ST did not result in any further increase in Isc, indicating a saturation pattern of the effect (Fig. 3A).

The concentration of ST stimulating a maximal response in Isc was the same for both mucosal and serosal addition (Fig. 3A). The addition of ST to the serosal side induced a rise in Isc that was very similar to that observed with mucosal addition with regard to the time course. However, the potency of maximal electrical effect was approximately 25% compared with that observed in response to mucosal addition (Fig. 2). Also in this model, the simultaneous addition of ST to both the mucosal and serosal compartments induced an Isc peak response that was not significantly increased compared with that observed with mucosal addition. All electrical modifications were inhibited in chloride-free buffer (Fig. 2).

Electrical effects of Guanylin in Caco-2 cells. The same experiments performed with ST were repeated using guanylin. The addition of guanylin (10^{-6} M) to the mucosal side of




Figure 3. (A) Effect of increasing concentrations of ST on Isc of Caco-2 cells. The addition of ST to the mucosal (◆) or serosal (■) side resulted in a dose-dependent increase of Isc. There were four experiments per dose. *Statistically significant vs controls ($p < 0.05$). (B) Effect of increasing concentrations of guanylin on Isc of Caco-2 cells. The addition of ST to the mucosal (◆) or serosal (■) side resulted in a dose-dependent increase of Isc. There were four experiments per dose. *Statistically significant vs controls ($p < 0.05$).

Caco-2 cells induced an increase of Isc (data not shown) closely resembling that observed with ST. However, the potency of guanylin was approximately 50% of that observed with ST at equimolar concentrations.

Guanylin addition to the serosal side also induced a rise in Isc, whose magnitude was approximately 30% of mucosal effect. The concentration of guanylin stimulating the maximal response in Isc was the same for both mucosal and serosal addition and corresponded to 10^{-6} M (Fig. 3B). When guanylin at a concentration of 10^{-6} M was simultaneously added to both the mucosal and serosal compartments, the magnitude of the Isc response was greater than that observed with addition to the mucosal side. However, the difference did not reach statistical significance. Therefore, all the features of guanylin-induced secretion were similar to that of ST, although the potency of the secretory effect was reduced.

Effects of mucosal or serosal addition of ST or guanylin on cGMP concentration. As shown in Figure 4, ST and guanylin stimulated the production of cGMP in a dose-dependent manner in Caco-2 cells. Maximal ST-stimulated cGMP production was observed with an ST concentration of 10^{-6} M added to the mucosal compartment, resulting in a 14-fold increase in cGMP levels. Comparatively, the maximal cGMP increase upon ST serosal addition was 9-fold (Fig. 4A). When guanylin was added, the maximal increase of cGMP was reduced compared with the effect obtained with *E. coli* ST (Fig. 4).




Figure 2. Time course of the effect of the addition of ST to the mucosal (◆) or serosal (■) compartments on Isc of Caco-2 cells mounted in an Ussing chamber. The addition of ST (10^{-6} M) (arrow) to each side of Caco-2 cells induced an increase in Isc that was similar to that observed in the rat model. The simultaneous addition of ST to the mucosal and serosal (Δ) compartments induced no further increase in Isc. No increase in Isc was observed, in the absence of Cl^- , upon either the mucosal (×) or serosal (data not shown) addition of ST. Mean and SD of the peak effect of ST in at least four experiments is shown in the inset (* $p < 0.05$ vs controls).




Figure 4. (A) Effect on cGMP concentration of the addition of ST to the mucosal (◆) or serosal (■) side of Caco-2 cells monolayers. ST induced an increase of cGMP concentration in a dose-dependent manner. The maximal increase was observed with 10^{-6} M of ST added to the mucosal or serosal compartment. There were four experiments per dose. *Statistically significant vs controls ($p < 0.05$). (B) The effects of guanylin showed the same pattern observed with ST. The magnitude of toxin effect was higher than that of its endogenous ligand. There were four experiments per dose. *Statistically significant vs controls ($p < 0.05$).

The simultaneous addition of ST or guanylin in a concentration of 10^{-6} M to both sides of the Caco-2 cells induced a slight further increase in cGMP, not statistically different from that observed upon mucosal addition (Fig. 5).

Therefore, the mucosal or serosal addition of ST or guanylin was associated with an increase of cGMP concentration that showed a dose-response pattern that was similar to that observed in Ussing chamber experiments.

ELISA Assay for ST. The fluid bathing the mucosal surface of epithelium mounted in Ussing chambers was collected after ST addition on the serosal side. It produced an ELISA negative ST, indicating that there was no transepithelial flux of the toxin (data not shown).

DISCUSSION

Our data show that ST is active when added to the serosal side of rat colon or Caco-2 cells and that its effect is similar to that induced by mucosal addition, although less potent. We used the rat proximal colon to perform our initial experiments because we had previously detected ^{125}I -ST binding activity in basolateral membranes purified from this intestinal segment (29). The time and kinetic features of the electrical effects observed in the present work were similar to those detected with mucosal ST addition and consistent with anion secretion. The complete loss of the effect in the absence of chloride supports this interpretation.

ST effects and its mechanisms were further investigated in Caco-2 cells, a well-established model to study intestinal secretion. The electrical response was similar to that observed in the animal model, suggesting that serosally applied ST works by a similar pathway compared with that stimulated by apical addition. We also investigated its mechanisms and comparatively examined the effects of mucosal and serosal ST addition. The dose of ST capable of inducing the maximal increase in *I*_{sc} on each side was identical. However, when maximal concentrations of ST were simultaneously added to the apical and basolateral compartments, the observed increase in *I*_{sc} was not different from that observed with ST mucosal addition alone. This indicates that the pathway of ST is the same, independent of the route of ST access to the enterocyte. This is strongly

supported by a cGMP determination that showed a pattern identical to electrical data. Together with our data on the specific binding activity in BLM of rat proximal colon (29), this suggests that the same secretory pathway involved in mucosal ST response is activated by a basolateral stimulus. However, the magnitude of both the electrical response and the increase in cGMP upon serosal addition were reduced compared with that induced by mucosal addition. This is consistent with our finding that the specific binding in BBM of rat proximal colon was higher than in BLM, suggesting a decreased receptor density in the latter (29). The similarity in the dose-response effect to mucosal or serosal ST addition does not fit with this interpretation. However, a broad range of ST concentrations was used and it is possible that minor kinetic differences, such as a different response with double ST concentrations, were not identified. Alternatively, because the maximal ST concentration was the same on either side but the effect was different, the possibility of a different receptor-effector coupling in the BLM may explain the observed results.

Our finding of a response to serosal ST addition differs from that reported by others (27,32–34). We have performed experiments to look for ST in the fluid bathing the mucosal surface of epithelium, after serosal ST addition. A transepithelial serosa-to-mucosa ST flux might have explained the observed results. We did not find any evidence of transepithelial flux of ST. We cannot explain why our data differ from that published by others other than the fact different cells and animal species were used.

Guanylin induced the same effects of ST, although its potency was reduced. A similar finding of a reduced secretion induced by a mucosal guanylin addition compared with ST has been reported previously (34). We observed the same difference in potency between the endogenous and exogenous GC-C ligands with the serosal application. Overall, our data therefore support the existence of a ST/guanylin-dependent activation pathway *via* the serosal route. The two ST-like endogenous ligands produced in the intestine, guanylin and uroguanylin, are released into the blood and may exert their effects on the serosal side of polarized enterocytes. Guanylin and uroguanylin are, in fact, secreted into the intestinal lumen as well as into the bloodstream in response to sodium chloride administration and may regulate ion and water transport in the intestine and kidney by luminocrine and endocrine actions (12–14).

An active role of the enterocyte in ion transport has been hypothesized (35). We have reported that the enterocyte responds to an enterotoxin-induced secretion through the activation of constitutive nitric oxide synthase functioning as a breaking force of ion secretion. The data in this article add to the concept that enterocytes play a major role in regulating ion transport. Guanylin and uroguanylin may regulate intestinal electrolyte homeostasis by acting on the serosal surface of the colonic mucosa as well as on the apical membrane of small intestinal enterocytes.

ST effector GC-C shows an age-related pattern and peak at the newborn stage (36). It may therefore be hypothesized that the ST/guanylin-receptor system could help prevent excessive growth and proliferation of potentially pathogenic microorgan-




Figure 5. Effects on cGMP concentration of the addition of ST (*left side*) and guanylin (*right side*) to the mucosal (■) and serosal (□) side and to both sides (▨) of Caco-2 cell monolayers. The simultaneous addition of ST or guanylin at concentration of 10^{-6} M to both sides of the Caco-2 cells induced a further increase in cGMP concentration that did not reach the level of statistical significance compared with that observed upon mucosal addition. *Statistically significant *vs* basal ($p < 0.05$).

isms through their washing out at an age in which the susceptibility to intestinal infection is highest.

Children with cystic fibrosis (CF) lack the CFTR anion channel and in these patients the colon is unresponsive to ST (37). The CF newborn infant has a high risk of intestinal obstruction due to impaction of meconium. We have previously shown that ST receptors have an age-related pattern, peaking in the first 3 d of life (38). This suggests that guanylin may have the additional specific function of promoting chloride secretion to allow meconium output.

In conclusion, the results of this work show that 1) ST and guanylin induce chloride secretion when added to the serosal side of intestinal epithelium; 2) the effect has similar kinetic features compared with mucosal addition, but is less potent; 3) the effect is not additive to that observed with mucosal addition, although a further minor increase in either Isc and cGMP is consistently observed; and 4) guanylin is less potent than ST as a secretagogue. Overall, the results of this work raise the hypothesis that the colon is a target organ for both the paracrine and the endocrine effects of guanylin, acting on either side of the epithelium to reduce absorption and induce net Cl^- secretion.

REFERENCES

- de Sauvage FJ, Camerato TR, Goeddel DV 1991 Primary structure and functional expression of the human receptor for *Escherichia coli* heat-stable enterotoxin. *J Biol Chem* 266:17912–17918
- Schulz S, Green CK, Yuen PS, Garbers DL 1990 Guanylyl cyclase is a heat-stable enterotoxin receptor. *Cell* 63:941–948
- Cohen MB, Giannella RA 1995 Enterotoxigenic *E. coli*. In: Blaser MJ, Smith PD, Ravdin JJ, Greenberg HB (eds) *Infections of the Gastrointestinal Tract*. New York, Raven Press, pp 691–707
- Field M, Graf LH Jr, Laird WJ, Smith PL 1978 Heat-stable enterotoxin of *Escherichia coli*: *in vitro* effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. *Proc Natl Acad Sci U S A* 75:2800–2804
- Rao MC, Guandalini S, Smith PL, Field M 1980 Mode of action of heat-stable *Escherichia coli* enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. *Biochim Biophys Acta* 632:35–46
- Vaandrager AB, Bot AG, de Jonge HR 1997 Guanosine 3',5'-cyclic monophosphate-dependent protein kinase II mediates heat-stable enterotoxin-provoked chloride secretion in rat intestine. *Gastroenterology* 112:437–443
- Vaandrager AB, Bot AG, Ruth P, Pfeifer A, Hofmann F, de Jonge HR 2000 Differential role of cyclic GMP-dependent protein kinase II in ion transport in murine small intestine and colon. *Gastroenterology* 118:108–114
- Kunzelmann K, Kiser GL, Schreiber R, Riordan JR 1997 Inhibition of epithelial Na^+ currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator. *FEBS Lett* 400:341–344
- Guarino A, Alessio M, Tarallo L, Fontana M, Iacono G, Gobio Casali L, Guandalini S 1989 Heat stable enterotoxin produced by *Escherichia coli* in acute diarrhoea. *Arch Dis Child* 64:808–813
- Currie MG, Fox KF, Kato J, Moore RJ, Hamra FK, Duffin KL, Smith CE 1992 Guanylin: an endogenous activator of intestinal guanylate cyclase. *Proc Natl Acad Sci U S A* 89:947–951
- Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA, Fok KF, Smith CE 1993 Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. *Proc Natl Acad Sci U S A* 90:10464–10468
- Whitaker TL, Witte DP, Scott MC, Cohen MB 1997 Uroguanylin and guanylin: distinct but overlapping patterns of messenger RNA expression in mouse intestine. *Gastroenterology* 113:1000–1006
- Cohen MB, Witte DP, Hawkins JA, Currie MG 1995 Immunohistochemical localization of guanylin in the rat small intestine and colon. *Biochem Biophys Res Commun* 209:803–808
- Fan X, Hamra FK, Freeman RH, Eber SL, Krause WJ, Lim RW, Pace VM, Currie MG, Forte LR 1996 Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. *Biochem Biophys Res Commun* 219:457–462
- Hamra FK, Fan X, Krause WJ, Freeman RH, Chin DT, Smith CE, Currie MG, Forte LR 1996 Prouroguanylin and Proguanylin: purification from colon, structure, and modulation of bioactivity by proteases. *Endocrinology* 137:257–265
- de Sauvage FJ, Keshav S, Kuang WJ, Gillett N, Henzel W, Goeddel DV 1992 Precursor structure, expression, and tissue distribution of human guanylin. *Proc Natl Acad Sci U S A* 89:9089–9093
- Schultz S, Chrisman TD, Garbers DL 1992 Cloning and expression of guanylin. Its existence in various mammalian tissues. *J Biol Chem* 267:16019–16021
- Fonteles MC, Greenberg RN, Monteiro HS, Currie MG, Forte LR 1998 Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. *Am J Physiol* 275:F191–F197
- Ohbayashi H, Yamaki K, Suzuki R, Takagi K 1998 Effects of uroguanylin and guanylin against antigen-induced bronchoconstriction and airway microvascular leakage in sensitized guinea-pigs. *Life Sci* 62:1833–1844
- Zhang ZH, Jow F, Numann R, Hinson J 1998 The airway-epithelium: a novel site of action by guanylin. *Biochem Biophys Res Commun* 244:50–56
- Cohen MB, Hawkins JA, Witte DP 1998 Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. *Lab Invest* 78:101–108
- Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR 2000 Uroguanylin treatment suppresses polyp formation in the APC^{min/+} mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. *Cancer Res* 60:5151–5157
- Wang Y, Eber SL, Rowland LM, Forte LR 2000 Uroguanylin induces apoptosis in human colon carcinoma cells via a cGMP-dependent mechanism. *FASEB J* 14:A360
- Giannella RA, Luttrell M, Thompson MR 1983 Binding of *Escherichia coli* heat-stable enterotoxin to receptors on rat intestinal cells. *Am J Physiol* 245:G492–G498
- Guarino A, Cohen MB, Overmann G, Thompson MR, Giannella RA 1987 Binding of *E. coli* heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. *Dig Dis Sci* 32:1017–1026
- Guarino A, Cohen M, Thompson M, Dharmasathaphorn K, Giannella RA 1987 T84 cell receptor binding and guanyl cyclase activation by *Escherichia coli* heat-stable enterotoxin. *Am J Physiol* 253:G775–G780
- Huott PA, Liu W, McRoberts JA, Giannella RA, Dharmasathaphorn K 1988 Mechanism of action of *Escherichia coli* heat-stable enterotoxin in a human colonic cell line. *J Clin Invest* 82:514–523
- Mezoff AG, Giannella RA, Eade MN, Cohen MB 1992 *Escherichia coli* enterotoxin (STa) binds to receptors, stimulates guanyl cyclase, and impairs absorption in rat colon. *Gastroenterology* 102:816–822
- Albano F, Brasitus T, Mann EA, Guarino A, Giannella RA 2001 Colonocyte basolateral membranes contain *Escherichia coli* heat-stable enterotoxin receptors. *Biochem Biophys Res Commun* 284:331–334
- Guarino A, Canani RB, Casola A, Pozio E, Russo R, Bruzzese E, Fontana M, Rubino A 1995 Human intestinal cryptosporidiosis: secretory diarrhea and enterotoxic activity in Caco-2 cells. *J Infect Dis* 171:976–983
- Thompson MR, Brandwein H, LaBine-Racke M, Giannella RA 1984 Simple and reliable enzyme-linked immunosorbent assay with monoclonal antibodies for detection of *Escherichia coli* heat stable enterotoxin. *J Clin Microbiol* 20:59–64
- Kuhn M, Adermann K, Jahne J, Forsmann WG, Rechkemmer G 1994 Segmental differences in the effect of guanylin and *Escherichia coli* heat-stable enterotoxin on Cl^- secretion in human gut. *J Physiol* 479:433–440
- Charney AN, Egnor RW, Alexander-Chacko JT, Zaharia V, Mann EA, Giannella RA 2001 Effect of *E. coli* heat-stable enterotoxin on colonic transport in guanylyl cyclase C receptor-deficient mice. *Am J Physiol Gastrointest Liver Physiol* 280:G216–G221
- Forte LR, Eber SL, Turner JT, Freeman RH, Fok KF, Currie MG 1993 Guanylin stimulation of Cl^- secretion in human intestinal T84 cells via cyclic guanosine monophosphate. *J Clin Invest* 91:2423–2428
- Canani RB, Cirillo P, Buccigrossi V, De Marco G, Mallardo G, Bruzzese E, Polito G, Guarino A 2003 Nitric oxide produced by the enterocyte is involved in the cellular regulation of ion transport. *Pediatr Res* 54:64–68
- Cohen MB, Guarino A, Shukla R, Giannella RA 1988 Age-related differences in receptors for *Escherichia coli* heat-stable enterotoxin in the small and large intestine of children. *Gastroenterology* 94:367–373
- Goldstein JL, Sahi J, Bhuvu M, Layden TJ, Rao MC 1994 *Escherichia coli* heat stable enterotoxin-mediated colonic Cl^- secretion is absent in cystic fibrosis. *Gastroenterology* 107:950–956
- Guarino A, Cohen MB, Giannella RA 1987 Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by *Escherichia coli* heat-stable enterotoxin. *Pediatr Res* 21:551–555